PD-1 (Czech Wikipedia)

Analysis of information sources in references of the Wikipedia article "PD-1" in Czech language version.

refsWebsite

Global rank Czech rank

46doi.org

2^nd place

4^th place

42worldcat.org

5^th place

3^rd place

37nih.gov

4^th place

8^th place

3jimmunol.org

low place

5,054^th place

3nature.com

234^th place

72^nd place

3elsevier.com

610^th place

203^rd place

2wiley.com

222^nd place

83^rd place

1uniprot.org

5,673^rd place

4,035^th place

1sciencemag.org

857^th place

315^th place

1web.archive.org

1^st place

doi.org

dx.doi.org

FIFE, Brian T.; PAUKEN, Kristen E. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Annals of the New York Academy of Sciences. 2011-01-01, roč. 1217, čís. 1, s. 45–59. Dostupné online [cit. 2018-01-25]. ISSN 1749-6632. DOI 10.1111/j.1749-6632.2010.05919.x. (anglicky)
FRANCISCO, Loise M.; SAGE, Peter T.; SHARPE, Arlene H. The PD-1 pathway in tolerance and autoimmunity. Immunological Reviews. 2010-07-01, roč. 236, čís. 1, s. 219–242. Dostupné online [cit. 2018-01-25]. ISSN 1600-065X. DOI 10.1111/j.1600-065x.2010.00923.x. (anglicky)
SYN, Nicholas L; TENG, Michele W L; MOK, Tony S K. De-novo and acquired resistance to immune checkpoint targeting. The Lancet Oncology. Roč. 18, čís. 12, s. e731–e741. Dostupné online [cit. 2018-01-24]. DOI 10.1016/s1470-2045(17)30607-1.
BARDHAN, Kankana; ANAGNOSTOU, Theodora; BOUSSIOTIS, Vassiliki A. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Frontiers in Immunology. 2016-12-12, roč. 7. PMID: 28018338 PMCID: PMC5149523. Dostupné online [cit. 2018-01-24]. ISSN 1664-3224. DOI 10.3389/fimmu.2016.00550. PMID 28018338.
SHINOHARA, T.; TANIWAKI, M.; ISHIDA, Y. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics. October 1994, roč. 23, čís. 3, s. 704–706. PMID: 7851902. Dostupné online [cit. 2018-01-24]. ISSN 0888-7543. DOI 10.1006/geno.1994.1562. PMID 7851902.
KEIR, Mary E.; BUTTE, Manish J.; FREEMAN, Gordon J. PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology. 2008, roč. 26, s. 677–704. PMID: 18173375. Dostupné online [cit. 2018-01-25]. ISSN 0732-0582. DOI 10.1146/annurev.immunol.26.021607.090331. PMID 18173375.
CHEMNITZ, Jens M.; PARRY, Richard V.; NICHOLS, Kim E. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. The Journal of Immunology. 2004-07-15, roč. 173, čís. 2, s. 945–954. PMID: 15240681. Dostupné online [cit. 2018-02-15]. ISSN 0022-1767. DOI 10.4049/jimmunol.173.2.945. PMID 15240681. (anglicky)
BARBER, Daniel L.; WHERRY, E. John; MASOPUST, David. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006/02, roč. 439, čís. 7077, s. 682–687. Dostupné online [cit. 2018-02-13]. ISSN 1476-4687. DOI 10.1038/nature04444. (En)
RILEY, James L. PD-1 signaling in primary T cells. Immunological Reviews. May 2009, roč. 229, čís. 1, s. 114–125. PMID: 19426218 PMCID: PMC3424066. Dostupné online [cit. 2018-01-24]. ISSN 1600-065X. DOI 10.1111/j.1600-065X.2009.00767.x. PMID 19426218.
CHEMNITZ, Jens M.; PARRY, Richard V.; NICHOLS, Kim E. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. The Journal of Immunology. 2004-07-15, roč. 173, čís. 2, s. 945–954. PMID: 15240681. Dostupné online [cit. 2018-01-25]. ISSN 0022-1767. DOI 10.4049/jimmunol.173.2.945. PMID 15240681. (anglicky)
NEEL, Benjamin G.; GU, Haihua; PAO, Lily. The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends in Biochemical Sciences. Roč. 28, čís. 6, s. 284–293. Dostupné online [cit. 2018-01-25]. DOI 10.1016/s0968-0004(03)00091-4.
KEIR, Mary E.; BUTTE, Manish J.; FREEMAN, Gordon J. PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology. 2008, roč. 26, s. 677–704. PMID: 18173375. Dostupné online [cit. 2018-02-07]. ISSN 0732-0582. DOI 10.1146/annurev.immunol.26.021607.090331. PMID 18173375.
ZHONG, Xuemei; TUMANG, Joseph R.; GAO, Wenda. PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding. European Journal of Immunology. September 2007, roč. 37, čís. 9, s. 2405–2410. PMID: 17683117. Dostupné online [cit. 2018-01-25]. ISSN 0014-2980. DOI 10.1002/eji.200737461. PMID 17683117.
LATCHMAN, Y.; WOOD, C. R.; CHERNOVA, T. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunology. March 2001, roč. 2, čís. 3, s. 261–268. PMID: 11224527. Dostupné online [cit. 2018-02-06]. ISSN 1529-2908. DOI 10.1038/85330. PMID 11224527.
KEIR, Mary E.; BUTTE, Manish J.; FREEMAN, Gordon J. PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology. 2008, roč. 26, s. 677–704. PMID: 18173375. Dostupné online [cit. 2018-02-14]. ISSN 0732-0582. DOI 10.1146/annurev.immunol.26.021607.090331. PMID 18173375.
HE, Jiabei; HU, Ying; HU, Mingming. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Scientific Reports. 2015-08-17, roč. 5, čís. 1. Dostupné online [cit. 2018-02-06]. ISSN 2045-2322. DOI 10.1038/srep13110. (En)
EPPIHIMER, Michael J.; GUNN, Jason; FREEMAN, Gordon J. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation (New York, N.Y.: 1994). April 2002, roč. 9, čís. 2, s. 133–145. PMID: 11932780 PMCID: PMC3740166. Dostupné online [cit. 2018-02-14]. ISSN 1073-9688. DOI 10.1038/sj/mn/7800123. PMID 11932780.
SCHREINER, Bettina; MITSDOERFFER, Meike; KIESEIER, Bernd C. Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. Journal of Neuroimmunology. Roč. 155, čís. 1–2, s. 172–182. Dostupné online [cit. 2018-02-14]. DOI 10.1016/j.jneuroim.2004.06.013.
LEE, Seung-Jin; JANG, Byeong-Churl; LEE, Soo-Woong. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS letters. 2006-02-06, roč. 580, čís. 3, s. 755–762. PMID: 16413538. Dostupné online [cit. 2018-02-14]. ISSN 0014-5793. DOI 10.1016/j.febslet.2005.12.093. PMID 16413538.
LIU, Jizhong; HAMROUNI, Abdelbasset; WOLOWIEC, Darius. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007-07-01, roč. 110, čís. 1, s. 296–304. PMID: 17363736. Dostupné online [cit. 2018-02-15]. ISSN 0006-4971. DOI 10.1182/blood-2006-10-051482. PMID 17363736.
PARSA, Andrew T.; WALDRON, James S.; PANNER, Amith. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nature Medicine. January 2007, roč. 13, čís. 1, s. 84–88. PMID: 17159987. Dostupné online [cit. 2018-02-14]. ISSN 1078-8956. DOI 10.1038/nm1517. PMID 17159987.
BARSOUM, Ivraym B.; SMALLWOOD, Chelsea A.; SIEMENS, D. Robert. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Research. 2014-02-01, roč. 74, čís. 3, s. 665–674. PMID: 24336068. Dostupné online [cit. 2018-02-14]. ISSN 1538-7445. DOI 10.1158/0008-5472.CAN-13-0992. PMID 24336068.
GATO-CAÑAS, Maria; ZUAZO, Miren; ARASANZ, Hugo. PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. Cell Reports. 2017, roč. 20, čís. 8, s. 1818–1829. Dostupné online [cit. 2018-02-14]. DOI 10.1016/j.celrep.2017.07.075.
HUI, Enfu; CHEUNG, Jeanne; ZHU, Jing. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science (New York, N.Y.). 03 31, 2017, roč. 355, čís. 6332, s. 1428–1433. PMID: 28280247. Dostupné online [cit. 2018-02-12]. ISSN 1095-9203. DOI 10.1126/science.aaf1292. PMID 28280247.
SHEPPARD, Kelly-Ann; FITZ, Lori J.; LEE, Julie M. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS letters. 2004-09-10, roč. 574, čís. 1–3, s. 37–41. PMID: 15358536. Dostupné online [cit. 2018-02-05]. ISSN 0014-5793. DOI 10.1016/j.febslet.2004.07.083. PMID 15358536.
PATSOUKIS, Nikolaos; BROWN, Julia; PETKOVA, Victoria. Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation. Science signaling. 2012-06-26, roč. 5, čís. 230, s. ra46. PMID: 22740686 PMCID: PMC5498435. Dostupné online [cit. 2018-02-05]. ISSN 1945-0877. DOI 10.1126/scisignal.2002796. PMID 22740686.
MATSUURA, Isao; DENISSOVA, Natalia G.; WANG, Guannan. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature. 2004/07, roč. 430, čís. 6996, s. 226–231. Dostupné online [cit. 2018-02-14]. ISSN 1476-4687. DOI 10.1038/nature02650. (En)
PARRY, Richard V.; CHEMNITZ, Jens M.; FRAUWIRTH, Kenneth A. CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms. Molecular and Cellular Biology. 2005-11, roč. 25, čís. 21, s. 9543–9553. PMID: 16227604 PMCID: PMC1265804. Dostupné online [cit. 2018-02-06]. ISSN 0270-7306. DOI 10.1128/MCB.25.21.9543-9553.2005. PMID 16227604.
CHEMNITZ, Jens M.; PARRY, Richard V.; NICHOLS, Kim E. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. The Journal of Immunology. 2004-07-15, roč. 173, čís. 2, s. 945–954. PMID: 15240681. Dostupné online [cit. 2018-02-06]. ISSN 0022-1767. DOI 10.4049/jimmunol.173.2.945. PMID 15240681. (anglicky)
STARON, Matthew M.; GRAY, Simon M.; MARSHALL, Heather D. The Transcription Factor FoxO1 Sustains Expression of the Inhibitory Receptor PD-1 and Survival of Antiviral CD8+ T Cells during Chronic Infection. Immunity. Roč. 41, čís. 5, s. 802–814. Dostupné online [cit. 2018-02-13]. DOI 10.1016/j.immuni.2014.10.013.
MICHALEK, Ryan D.; GERRIETS, Valerie A.; JACOBS, Sarah R. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. Journal of Immunology (Baltimore, Md.: 1950). 2011-03-15, roč. 186, čís. 6, s. 3299–3303. PMID: 21317389 PMCID: PMC3198034. Dostupné online [cit. 2018-02-05]. ISSN 1550-6606. DOI 10.4049/jimmunol.1003613. PMID 21317389.
PATSOUKIS, Nikolaos; BARDHAN, Kankana; CHATTERJEE, Pranam. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nature Communications. 2015-03-26, roč. 6. PMID: 25809635 PMCID: PMC4389235. Dostupné online [cit. 2018-02-05]. ISSN 2041-1723. DOI 10.1038/ncomms7692. PMID 25809635.
AMARNATH, Shoba; MANGUS, Courtney W.; WANG, James C. M. The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells. Science Translational Medicine. 2011-11-30, roč. 3, čís. 111, s. 111ra120–111ra120. PMID: 22133721. Dostupné online [cit. 2018-02-14]. ISSN 1946-6234. DOI 10.1126/scitranslmed.3003130. PMID 22133721. (anglicky) Archivováno 1. 6. 2018 na Wayback Machine.
NURIEVA, Roza; THOMAS, Sunil; NGUYEN, Thang. T-cell tolerance or function is determined by combinatorial costimulatory signals. The EMBO Journal. 2006-06-07, roč. 25, čís. 11, s. 2623–2633. PMID: 16724117 PMCID: PMC1478197. Dostupné online [cit. 2018-02-14]. ISSN 0261-4189. DOI 10.1038/sj.emboj.7601146. PMID 16724117.
WANG, Xin; TENG, Feifei; KONG, Li. PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets and Therapy. 2016, roč. 9, s. 5023–5039. PMID: 27574444 PMCID: PMC4990391. Dostupné online [cit. 2019-02-10]. ISSN 1178-6930. DOI 10.2147/OTT.S105862. PMID 27574444.
GANDINI, Sara; MASSI, Daniela; MANDALÀ, Mario. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 2016-4, roč. 100, s. 88–98. PMID: 26895815. Dostupné online [cit. 2019-02-10]. ISSN 1879-0461. DOI 10.1016/j.critrevonc.2016.02.001. PMID 26895815.
SYN, Nicholas L.; TENG, Michele W. L.; MOK, Tony S. K. De-novo and acquired resistance to immune checkpoint targeting. The Lancet. Oncology. 12 2017, roč. 18, čís. 12, s. e731–e741. PMID: 29208439. Dostupné online [cit. 2019-02-10]. ISSN 1474-5488. DOI 10.1016/S1470-2045(17)30607-1. PMID 29208439.
WEBER, Jeffrey. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Seminars in Oncology. 2010-10, roč. 37, čís. 5, s. 430–439. PMID: 21074057. Dostupné online [cit. 2019-02-10]. ISSN 1532-8708. DOI 10.1053/j.seminoncol.2010.09.005. PMID 21074057.
HERBST, Roy S.; SORIA, Jean-Charles; KOWANETZ, Marcin. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014-11-27, roč. 515, čís. 7528, s. 563–567. PMID: 25428504 PMCID: PMC4836193. Dostupné online [cit. 2019-02-10]. ISSN 1476-4687. DOI 10.1038/nature14011. PMID 25428504.
SNYDER, Alexandra; MAKAROV, Vladimir; MERGHOUB, Taha. Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England Journal of Medicine. 2014-12-04, roč. 371, čís. 23, s. 2189–2199. PMID: 25409260 PMCID: PMC4315319. Dostupné online [cit. 2019-02-10]. ISSN 1533-4406. DOI 10.1056/NEJMoa1406498. PMID 25409260.
BUCHBINDER, Elizabeth I.; DESAI, Anupam. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. American Journal of Clinical Oncology. 2016-2, roč. 39, čís. 1, s. 98–106. PMID: 26558876 PMCID: PMC4892769. Dostupné online [cit. 2019-02-10]. ISSN 1537-453X. DOI 10.1097/COC.0000000000000239. PMID 26558876.
TOPALIAN, Suzanne L.; TAUBE, Janis M.; ANDERS, Robert A. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews. Cancer. 05 2016, roč. 16, čís. 5, s. 275–287. PMID: 27079802 PMCID: PMC5381938. Dostupné online [cit. 2019-02-10]. ISSN 1474-1768. DOI 10.1038/nrc.2016.36. PMID 27079802.
CHEN, Daniel S.; MELLMAN, Ira. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013-07-25, roč. 39, čís. 1, s. 1–10. PMID: 23890059. Dostupné online [cit. 2019-02-10]. ISSN 1097-4180. DOI 10.1016/j.immuni.2013.07.012. PMID 23890059.
CURRAN, Michael A.; MONTALVO, Welby; YAGITA, Hideo. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceedings of the National Academy of Sciences of the United States of America. 2010-03-02, roč. 107, čís. 9, s. 4275–4280. PMID: 20160101 PMCID: PMC2840093. Dostupné online [cit. 2019-02-10]. ISSN 1091-6490. DOI 10.1073/pnas.0915174107. PMID 20160101.

doi.org

SYN, Nicholas L; TENG, Michele W L; MOK, Tony S K. De-novo and acquired resistance to immune checkpoint targeting. The Lancet Oncology. Roč. 18, čís. 12, s. e731–e741. Dostupné online [cit. 2018-01-24]. DOI 10.1016/s1470-2045(17)30607-1.
NEEL, Benjamin G.; GU, Haihua; PAO, Lily. The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends in Biochemical Sciences. Roč. 28, čís. 6, s. 284–293. Dostupné online [cit. 2018-01-25]. DOI 10.1016/s0968-0004(03)00091-4.

elsevier.com

linkinghub.elsevier.com

SCHREINER, Bettina; MITSDOERFFER, Meike; KIESEIER, Bernd C. Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. Journal of Neuroimmunology. Roč. 155, čís. 1–2, s. 172–182. Dostupné online [cit. 2018-02-14]. DOI 10.1016/j.jneuroim.2004.06.013.
GATO-CAÑAS, Maria; ZUAZO, Miren; ARASANZ, Hugo. PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. Cell Reports. 2017, roč. 20, čís. 8, s. 1818–1829. Dostupné online [cit. 2018-02-14]. DOI 10.1016/j.celrep.2017.07.075.
STARON, Matthew M.; GRAY, Simon M.; MARSHALL, Heather D. The Transcription Factor FoxO1 Sustains Expression of the Inhibitory Receptor PD-1 and Survival of Antiviral CD8+ T Cells during Chronic Infection. Immunity. Roč. 41, čís. 5, s. 802–814. Dostupné online [cit. 2018-02-13]. DOI 10.1016/j.immuni.2014.10.013.

jimmunol.org

CHEMNITZ, Jens M.; PARRY, Richard V.; NICHOLS, Kim E. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. The Journal of Immunology. 2004-07-15, roč. 173, čís. 2, s. 945–954. PMID: 15240681. Dostupné online [cit. 2018-02-15]. ISSN 0022-1767. DOI 10.4049/jimmunol.173.2.945. PMID 15240681. (anglicky)
CHEMNITZ, Jens M.; PARRY, Richard V.; NICHOLS, Kim E. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. The Journal of Immunology. 2004-07-15, roč. 173, čís. 2, s. 945–954. PMID: 15240681. Dostupné online [cit. 2018-01-25]. ISSN 0022-1767. DOI 10.4049/jimmunol.173.2.945. PMID 15240681. (anglicky)
CHEMNITZ, Jens M.; PARRY, Richard V.; NICHOLS, Kim E. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. The Journal of Immunology. 2004-07-15, roč. 173, čís. 2, s. 945–954. PMID: 15240681. Dostupné online [cit. 2018-02-06]. ISSN 0022-1767. DOI 10.4049/jimmunol.173.2.945. PMID 15240681. (anglicky)

nature.com

BARBER, Daniel L.; WHERRY, E. John; MASOPUST, David. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006/02, roč. 439, čís. 7077, s. 682–687. Dostupné online [cit. 2018-02-13]. ISSN 1476-4687. DOI 10.1038/nature04444. (En)
HE, Jiabei; HU, Ying; HU, Mingming. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Scientific Reports. 2015-08-17, roč. 5, čís. 1. Dostupné online [cit. 2018-02-06]. ISSN 2045-2322. DOI 10.1038/srep13110. (En)
MATSUURA, Isao; DENISSOVA, Natalia G.; WANG, Guannan. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature. 2004/07, roč. 430, čís. 6996, s. 226–231. Dostupné online [cit. 2018-02-14]. ISSN 1476-4687. DOI 10.1038/nature02650. (En)

nih.gov

ncbi.nlm.nih.gov

BARDHAN, Kankana; ANAGNOSTOU, Theodora; BOUSSIOTIS, Vassiliki A. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Frontiers in Immunology. 2016-12-12, roč. 7. PMID: 28018338 PMCID: PMC5149523. Dostupné online [cit. 2018-01-24]. ISSN 1664-3224. DOI 10.3389/fimmu.2016.00550. PMID 28018338.
SHINOHARA, T.; TANIWAKI, M.; ISHIDA, Y. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics. October 1994, roč. 23, čís. 3, s. 704–706. PMID: 7851902. Dostupné online [cit. 2018-01-24]. ISSN 0888-7543. DOI 10.1006/geno.1994.1562. PMID 7851902.
KEIR, Mary E.; BUTTE, Manish J.; FREEMAN, Gordon J. PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology. 2008, roč. 26, s. 677–704. PMID: 18173375. Dostupné online [cit. 2018-01-25]. ISSN 0732-0582. DOI 10.1146/annurev.immunol.26.021607.090331. PMID 18173375.
CHEMNITZ, Jens M.; PARRY, Richard V.; NICHOLS, Kim E. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. The Journal of Immunology. 2004-07-15, roč. 173, čís. 2, s. 945–954. PMID: 15240681. Dostupné online [cit. 2018-02-15]. ISSN 0022-1767. DOI 10.4049/jimmunol.173.2.945. PMID 15240681. (anglicky)
ZHANG, Xuewu; SCHWARTZ, Jean-Claude D.; GUO, Xiaoling. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity. March 2004, roč. 20, čís. 3, s. 337–347. PMID: 15030777. Dostupné online [cit. 2018-01-24]. ISSN 1074-7613. PMID 15030777.
RILEY, James L. PD-1 signaling in primary T cells. Immunological Reviews. May 2009, roč. 229, čís. 1, s. 114–125. PMID: 19426218 PMCID: PMC3424066. Dostupné online [cit. 2018-01-24]. ISSN 1600-065X. DOI 10.1111/j.1600-065X.2009.00767.x. PMID 19426218.
CHEMNITZ, Jens M.; PARRY, Richard V.; NICHOLS, Kim E. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. The Journal of Immunology. 2004-07-15, roč. 173, čís. 2, s. 945–954. PMID: 15240681. Dostupné online [cit. 2018-01-25]. ISSN 0022-1767. DOI 10.4049/jimmunol.173.2.945. PMID 15240681. (anglicky)
KEIR, Mary E.; BUTTE, Manish J.; FREEMAN, Gordon J. PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology. 2008, roč. 26, s. 677–704. PMID: 18173375. Dostupné online [cit. 2018-02-07]. ISSN 0732-0582. DOI 10.1146/annurev.immunol.26.021607.090331. PMID 18173375.
ZHONG, Xuemei; TUMANG, Joseph R.; GAO, Wenda. PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding. European Journal of Immunology. September 2007, roč. 37, čís. 9, s. 2405–2410. PMID: 17683117. Dostupné online [cit. 2018-01-25]. ISSN 0014-2980. DOI 10.1002/eji.200737461. PMID 17683117.
LATCHMAN, Y.; WOOD, C. R.; CHERNOVA, T. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunology. March 2001, roč. 2, čís. 3, s. 261–268. PMID: 11224527. Dostupné online [cit. 2018-02-06]. ISSN 1529-2908. DOI 10.1038/85330. PMID 11224527.
YAMAZAKI, Tomohide; AKIBA, Hisaya; IWAI, Hideyuki. Expression of programmed death 1 ligands by murine T cells and APC. Journal of Immunology (Baltimore, Md.: 1950). 2002-11-15, roč. 169, čís. 10, s. 5538–5545. PMID: 12421930. Dostupné online [cit. 2018-02-14]. ISSN 0022-1767. PMID 12421930.
KEIR, Mary E.; BUTTE, Manish J.; FREEMAN, Gordon J. PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology. 2008, roč. 26, s. 677–704. PMID: 18173375. Dostupné online [cit. 2018-02-14]. ISSN 0732-0582. DOI 10.1146/annurev.immunol.26.021607.090331. PMID 18173375.
EPPIHIMER, Michael J.; GUNN, Jason; FREEMAN, Gordon J. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation (New York, N.Y.: 1994). April 2002, roč. 9, čís. 2, s. 133–145. PMID: 11932780 PMCID: PMC3740166. Dostupné online [cit. 2018-02-14]. ISSN 1073-9688. DOI 10.1038/sj/mn/7800123. PMID 11932780.
LEE, Seung-Jin; JANG, Byeong-Churl; LEE, Soo-Woong. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS letters. 2006-02-06, roč. 580, čís. 3, s. 755–762. PMID: 16413538. Dostupné online [cit. 2018-02-14]. ISSN 0014-5793. DOI 10.1016/j.febslet.2005.12.093. PMID 16413538.
LIU, Jizhong; HAMROUNI, Abdelbasset; WOLOWIEC, Darius. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007-07-01, roč. 110, čís. 1, s. 296–304. PMID: 17363736. Dostupné online [cit. 2018-02-15]. ISSN 0006-4971. DOI 10.1182/blood-2006-10-051482. PMID 17363736.
PARSA, Andrew T.; WALDRON, James S.; PANNER, Amith. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nature Medicine. January 2007, roč. 13, čís. 1, s. 84–88. PMID: 17159987. Dostupné online [cit. 2018-02-14]. ISSN 1078-8956. DOI 10.1038/nm1517. PMID 17159987.
BARSOUM, Ivraym B.; SMALLWOOD, Chelsea A.; SIEMENS, D. Robert. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Research. 2014-02-01, roč. 74, čís. 3, s. 665–674. PMID: 24336068. Dostupné online [cit. 2018-02-14]. ISSN 1538-7445. DOI 10.1158/0008-5472.CAN-13-0992. PMID 24336068.
HUI, Enfu; CHEUNG, Jeanne; ZHU, Jing. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science (New York, N.Y.). 03 31, 2017, roč. 355, čís. 6332, s. 1428–1433. PMID: 28280247. Dostupné online [cit. 2018-02-12]. ISSN 1095-9203. DOI 10.1126/science.aaf1292. PMID 28280247.
SHEPPARD, Kelly-Ann; FITZ, Lori J.; LEE, Julie M. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS letters. 2004-09-10, roč. 574, čís. 1–3, s. 37–41. PMID: 15358536. Dostupné online [cit. 2018-02-05]. ISSN 0014-5793. DOI 10.1016/j.febslet.2004.07.083. PMID 15358536.
PATSOUKIS, Nikolaos; BROWN, Julia; PETKOVA, Victoria. Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation. Science signaling. 2012-06-26, roč. 5, čís. 230, s. ra46. PMID: 22740686 PMCID: PMC5498435. Dostupné online [cit. 2018-02-05]. ISSN 1945-0877. DOI 10.1126/scisignal.2002796. PMID 22740686.
PARRY, Richard V.; CHEMNITZ, Jens M.; FRAUWIRTH, Kenneth A. CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms. Molecular and Cellular Biology. 2005-11, roč. 25, čís. 21, s. 9543–9553. PMID: 16227604 PMCID: PMC1265804. Dostupné online [cit. 2018-02-06]. ISSN 0270-7306. DOI 10.1128/MCB.25.21.9543-9553.2005. PMID 16227604.
BOISE, L. H.; MINN, A. J.; NOEL, P. J. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity. July 1995, roč. 3, čís. 1, s. 87–98. PMID: 7621080. Dostupné online [cit. 2018-02-06]. ISSN 1074-7613. PMID 7621080.
CHEMNITZ, Jens M.; PARRY, Richard V.; NICHOLS, Kim E. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. The Journal of Immunology. 2004-07-15, roč. 173, čís. 2, s. 945–954. PMID: 15240681. Dostupné online [cit. 2018-02-06]. ISSN 0022-1767. DOI 10.4049/jimmunol.173.2.945. PMID 15240681. (anglicky)
MICHALEK, Ryan D.; GERRIETS, Valerie A.; JACOBS, Sarah R. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. Journal of Immunology (Baltimore, Md.: 1950). 2011-03-15, roč. 186, čís. 6, s. 3299–3303. PMID: 21317389 PMCID: PMC3198034. Dostupné online [cit. 2018-02-05]. ISSN 1550-6606. DOI 10.4049/jimmunol.1003613. PMID 21317389.
PATSOUKIS, Nikolaos; BARDHAN, Kankana; CHATTERJEE, Pranam. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nature Communications. 2015-03-26, roč. 6. PMID: 25809635 PMCID: PMC4389235. Dostupné online [cit. 2018-02-05]. ISSN 2041-1723. DOI 10.1038/ncomms7692. PMID 25809635.
AMARNATH, Shoba; MANGUS, Courtney W.; WANG, James C. M. The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells. Science Translational Medicine. 2011-11-30, roč. 3, čís. 111, s. 111ra120–111ra120. PMID: 22133721. Dostupné online [cit. 2018-02-14]. ISSN 1946-6234. DOI 10.1126/scitranslmed.3003130. PMID 22133721. (anglicky) Archivováno 1. 6. 2018 na Wayback Machine.
NURIEVA, Roza; THOMAS, Sunil; NGUYEN, Thang. T-cell tolerance or function is determined by combinatorial costimulatory signals. The EMBO Journal. 2006-06-07, roč. 25, čís. 11, s. 2623–2633. PMID: 16724117 PMCID: PMC1478197. Dostupné online [cit. 2018-02-14]. ISSN 0261-4189. DOI 10.1038/sj.emboj.7601146. PMID 16724117.
WANG, Xin; TENG, Feifei; KONG, Li. PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets and Therapy. 2016, roč. 9, s. 5023–5039. PMID: 27574444 PMCID: PMC4990391. Dostupné online [cit. 2019-02-10]. ISSN 1178-6930. DOI 10.2147/OTT.S105862. PMID 27574444.
GANDINI, Sara; MASSI, Daniela; MANDALÀ, Mario. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 2016-4, roč. 100, s. 88–98. PMID: 26895815. Dostupné online [cit. 2019-02-10]. ISSN 1879-0461. DOI 10.1016/j.critrevonc.2016.02.001. PMID 26895815.
SYN, Nicholas L.; TENG, Michele W. L.; MOK, Tony S. K. De-novo and acquired resistance to immune checkpoint targeting. The Lancet. Oncology. 12 2017, roč. 18, čís. 12, s. e731–e741. PMID: 29208439. Dostupné online [cit. 2019-02-10]. ISSN 1474-5488. DOI 10.1016/S1470-2045(17)30607-1. PMID 29208439.
WEBER, Jeffrey. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Seminars in Oncology. 2010-10, roč. 37, čís. 5, s. 430–439. PMID: 21074057. Dostupné online [cit. 2019-02-10]. ISSN 1532-8708. DOI 10.1053/j.seminoncol.2010.09.005. PMID 21074057.
HERBST, Roy S.; SORIA, Jean-Charles; KOWANETZ, Marcin. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014-11-27, roč. 515, čís. 7528, s. 563–567. PMID: 25428504 PMCID: PMC4836193. Dostupné online [cit. 2019-02-10]. ISSN 1476-4687. DOI 10.1038/nature14011. PMID 25428504.
SNYDER, Alexandra; MAKAROV, Vladimir; MERGHOUB, Taha. Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England Journal of Medicine. 2014-12-04, roč. 371, čís. 23, s. 2189–2199. PMID: 25409260 PMCID: PMC4315319. Dostupné online [cit. 2019-02-10]. ISSN 1533-4406. DOI 10.1056/NEJMoa1406498. PMID 25409260.
BUCHBINDER, Elizabeth I.; DESAI, Anupam. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. American Journal of Clinical Oncology. 2016-2, roč. 39, čís. 1, s. 98–106. PMID: 26558876 PMCID: PMC4892769. Dostupné online [cit. 2019-02-10]. ISSN 1537-453X. DOI 10.1097/COC.0000000000000239. PMID 26558876.
TOPALIAN, Suzanne L.; TAUBE, Janis M.; ANDERS, Robert A. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews. Cancer. 05 2016, roč. 16, čís. 5, s. 275–287. PMID: 27079802 PMCID: PMC5381938. Dostupné online [cit. 2019-02-10]. ISSN 1474-1768. DOI 10.1038/nrc.2016.36. PMID 27079802.
CHEN, Daniel S.; MELLMAN, Ira. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013-07-25, roč. 39, čís. 1, s. 1–10. PMID: 23890059. Dostupné online [cit. 2019-02-10]. ISSN 1097-4180. DOI 10.1016/j.immuni.2013.07.012. PMID 23890059.
CURRAN, Michael A.; MONTALVO, Welby; YAGITA, Hideo. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceedings of the National Academy of Sciences of the United States of America. 2010-03-02, roč. 107, čís. 9, s. 4275–4280. PMID: 20160101 PMCID: PMC2840093. Dostupné online [cit. 2019-02-10]. ISSN 1091-6490. DOI 10.1073/pnas.0915174107. PMID 20160101.

sciencemag.org

stm.sciencemag.org

AMARNATH, Shoba; MANGUS, Courtney W.; WANG, James C. M. The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells. Science Translational Medicine. 2011-11-30, roč. 3, čís. 111, s. 111ra120–111ra120. PMID: 22133721. Dostupné online [cit. 2018-02-14]. ISSN 1946-6234. DOI 10.1126/scitranslmed.3003130. PMID 22133721. (anglicky) Archivováno 1. 6. 2018 na Wayback Machine.

uniprot.org

PDCD1 - Programmed cell death protein 1 precursor - Homo sapiens (Human) - PDCD1 gene & protein. www.uniprot.org [online]. [cit. 2018-01-25]. Dostupné online. (anglicky)

web.archive.org

AMARNATH, Shoba; MANGUS, Courtney W.; WANG, James C. M. The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells. Science Translational Medicine. 2011-11-30, roč. 3, čís. 111, s. 111ra120–111ra120. PMID: 22133721. Dostupné online [cit. 2018-02-14]. ISSN 1946-6234. DOI 10.1126/scitranslmed.3003130. PMID 22133721. (anglicky) Archivováno 1. 6. 2018 na Wayback Machine.

wiley.com

onlinelibrary.wiley.com

FIFE, Brian T.; PAUKEN, Kristen E. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Annals of the New York Academy of Sciences. 2011-01-01, roč. 1217, čís. 1, s. 45–59. Dostupné online [cit. 2018-01-25]. ISSN 1749-6632. DOI 10.1111/j.1749-6632.2010.05919.x. (anglicky)
FRANCISCO, Loise M.; SAGE, Peter T.; SHARPE, Arlene H. The PD-1 pathway in tolerance and autoimmunity. Immunological Reviews. 2010-07-01, roč. 236, čís. 1, s. 219–242. Dostupné online [cit. 2018-01-25]. ISSN 1600-065X. DOI 10.1111/j.1600-065x.2010.00923.x. (anglicky)

worldcat.org

FIFE, Brian T.; PAUKEN, Kristen E. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Annals of the New York Academy of Sciences. 2011-01-01, roč. 1217, čís. 1, s. 45–59. Dostupné online [cit. 2018-01-25]. ISSN 1749-6632. DOI 10.1111/j.1749-6632.2010.05919.x. (anglicky)
FRANCISCO, Loise M.; SAGE, Peter T.; SHARPE, Arlene H. The PD-1 pathway in tolerance and autoimmunity. Immunological Reviews. 2010-07-01, roč. 236, čís. 1, s. 219–242. Dostupné online [cit. 2018-01-25]. ISSN 1600-065X. DOI 10.1111/j.1600-065x.2010.00923.x. (anglicky)
BARDHAN, Kankana; ANAGNOSTOU, Theodora; BOUSSIOTIS, Vassiliki A. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Frontiers in Immunology. 2016-12-12, roč. 7. PMID: 28018338 PMCID: PMC5149523. Dostupné online [cit. 2018-01-24]. ISSN 1664-3224. DOI 10.3389/fimmu.2016.00550. PMID 28018338.
SHINOHARA, T.; TANIWAKI, M.; ISHIDA, Y. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics. October 1994, roč. 23, čís. 3, s. 704–706. PMID: 7851902. Dostupné online [cit. 2018-01-24]. ISSN 0888-7543. DOI 10.1006/geno.1994.1562. PMID 7851902.
KEIR, Mary E.; BUTTE, Manish J.; FREEMAN, Gordon J. PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology. 2008, roč. 26, s. 677–704. PMID: 18173375. Dostupné online [cit. 2018-01-25]. ISSN 0732-0582. DOI 10.1146/annurev.immunol.26.021607.090331. PMID 18173375.
CHEMNITZ, Jens M.; PARRY, Richard V.; NICHOLS, Kim E. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. The Journal of Immunology. 2004-07-15, roč. 173, čís. 2, s. 945–954. PMID: 15240681. Dostupné online [cit. 2018-02-15]. ISSN 0022-1767. DOI 10.4049/jimmunol.173.2.945. PMID 15240681. (anglicky)
BARBER, Daniel L.; WHERRY, E. John; MASOPUST, David. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006/02, roč. 439, čís. 7077, s. 682–687. Dostupné online [cit. 2018-02-13]. ISSN 1476-4687. DOI 10.1038/nature04444. (En)
ZHANG, Xuewu; SCHWARTZ, Jean-Claude D.; GUO, Xiaoling. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity. March 2004, roč. 20, čís. 3, s. 337–347. PMID: 15030777. Dostupné online [cit. 2018-01-24]. ISSN 1074-7613. PMID 15030777.
RILEY, James L. PD-1 signaling in primary T cells. Immunological Reviews. May 2009, roč. 229, čís. 1, s. 114–125. PMID: 19426218 PMCID: PMC3424066. Dostupné online [cit. 2018-01-24]. ISSN 1600-065X. DOI 10.1111/j.1600-065X.2009.00767.x. PMID 19426218.
CHEMNITZ, Jens M.; PARRY, Richard V.; NICHOLS, Kim E. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. The Journal of Immunology. 2004-07-15, roč. 173, čís. 2, s. 945–954. PMID: 15240681. Dostupné online [cit. 2018-01-25]. ISSN 0022-1767. DOI 10.4049/jimmunol.173.2.945. PMID 15240681. (anglicky)
KEIR, Mary E.; BUTTE, Manish J.; FREEMAN, Gordon J. PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology. 2008, roč. 26, s. 677–704. PMID: 18173375. Dostupné online [cit. 2018-02-07]. ISSN 0732-0582. DOI 10.1146/annurev.immunol.26.021607.090331. PMID 18173375.
ZHONG, Xuemei; TUMANG, Joseph R.; GAO, Wenda. PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding. European Journal of Immunology. September 2007, roč. 37, čís. 9, s. 2405–2410. PMID: 17683117. Dostupné online [cit. 2018-01-25]. ISSN 0014-2980. DOI 10.1002/eji.200737461. PMID 17683117.
LATCHMAN, Y.; WOOD, C. R.; CHERNOVA, T. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunology. March 2001, roč. 2, čís. 3, s. 261–268. PMID: 11224527. Dostupné online [cit. 2018-02-06]. ISSN 1529-2908. DOI 10.1038/85330. PMID 11224527.
YAMAZAKI, Tomohide; AKIBA, Hisaya; IWAI, Hideyuki. Expression of programmed death 1 ligands by murine T cells and APC. Journal of Immunology (Baltimore, Md.: 1950). 2002-11-15, roč. 169, čís. 10, s. 5538–5545. PMID: 12421930. Dostupné online [cit. 2018-02-14]. ISSN 0022-1767. PMID 12421930.
KEIR, Mary E.; BUTTE, Manish J.; FREEMAN, Gordon J. PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology. 2008, roč. 26, s. 677–704. PMID: 18173375. Dostupné online [cit. 2018-02-14]. ISSN 0732-0582. DOI 10.1146/annurev.immunol.26.021607.090331. PMID 18173375.
HE, Jiabei; HU, Ying; HU, Mingming. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Scientific Reports. 2015-08-17, roč. 5, čís. 1. Dostupné online [cit. 2018-02-06]. ISSN 2045-2322. DOI 10.1038/srep13110. (En)
EPPIHIMER, Michael J.; GUNN, Jason; FREEMAN, Gordon J. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation (New York, N.Y.: 1994). April 2002, roč. 9, čís. 2, s. 133–145. PMID: 11932780 PMCID: PMC3740166. Dostupné online [cit. 2018-02-14]. ISSN 1073-9688. DOI 10.1038/sj/mn/7800123. PMID 11932780.
LEE, Seung-Jin; JANG, Byeong-Churl; LEE, Soo-Woong. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS letters. 2006-02-06, roč. 580, čís. 3, s. 755–762. PMID: 16413538. Dostupné online [cit. 2018-02-14]. ISSN 0014-5793. DOI 10.1016/j.febslet.2005.12.093. PMID 16413538.
LIU, Jizhong; HAMROUNI, Abdelbasset; WOLOWIEC, Darius. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007-07-01, roč. 110, čís. 1, s. 296–304. PMID: 17363736. Dostupné online [cit. 2018-02-15]. ISSN 0006-4971. DOI 10.1182/blood-2006-10-051482. PMID 17363736.
PARSA, Andrew T.; WALDRON, James S.; PANNER, Amith. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nature Medicine. January 2007, roč. 13, čís. 1, s. 84–88. PMID: 17159987. Dostupné online [cit. 2018-02-14]. ISSN 1078-8956. DOI 10.1038/nm1517. PMID 17159987.
BARSOUM, Ivraym B.; SMALLWOOD, Chelsea A.; SIEMENS, D. Robert. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Research. 2014-02-01, roč. 74, čís. 3, s. 665–674. PMID: 24336068. Dostupné online [cit. 2018-02-14]. ISSN 1538-7445. DOI 10.1158/0008-5472.CAN-13-0992. PMID 24336068.
HUI, Enfu; CHEUNG, Jeanne; ZHU, Jing. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science (New York, N.Y.). 03 31, 2017, roč. 355, čís. 6332, s. 1428–1433. PMID: 28280247. Dostupné online [cit. 2018-02-12]. ISSN 1095-9203. DOI 10.1126/science.aaf1292. PMID 28280247.
SHEPPARD, Kelly-Ann; FITZ, Lori J.; LEE, Julie M. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS letters. 2004-09-10, roč. 574, čís. 1–3, s. 37–41. PMID: 15358536. Dostupné online [cit. 2018-02-05]. ISSN 0014-5793. DOI 10.1016/j.febslet.2004.07.083. PMID 15358536.
PATSOUKIS, Nikolaos; BROWN, Julia; PETKOVA, Victoria. Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation. Science signaling. 2012-06-26, roč. 5, čís. 230, s. ra46. PMID: 22740686 PMCID: PMC5498435. Dostupné online [cit. 2018-02-05]. ISSN 1945-0877. DOI 10.1126/scisignal.2002796. PMID 22740686.
MATSUURA, Isao; DENISSOVA, Natalia G.; WANG, Guannan. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature. 2004/07, roč. 430, čís. 6996, s. 226–231. Dostupné online [cit. 2018-02-14]. ISSN 1476-4687. DOI 10.1038/nature02650. (En)
PARRY, Richard V.; CHEMNITZ, Jens M.; FRAUWIRTH, Kenneth A. CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms. Molecular and Cellular Biology. 2005-11, roč. 25, čís. 21, s. 9543–9553. PMID: 16227604 PMCID: PMC1265804. Dostupné online [cit. 2018-02-06]. ISSN 0270-7306. DOI 10.1128/MCB.25.21.9543-9553.2005. PMID 16227604.
BOISE, L. H.; MINN, A. J.; NOEL, P. J. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity. July 1995, roč. 3, čís. 1, s. 87–98. PMID: 7621080. Dostupné online [cit. 2018-02-06]. ISSN 1074-7613. PMID 7621080.
CHEMNITZ, Jens M.; PARRY, Richard V.; NICHOLS, Kim E. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. The Journal of Immunology. 2004-07-15, roč. 173, čís. 2, s. 945–954. PMID: 15240681. Dostupné online [cit. 2018-02-06]. ISSN 0022-1767. DOI 10.4049/jimmunol.173.2.945. PMID 15240681. (anglicky)
MICHALEK, Ryan D.; GERRIETS, Valerie A.; JACOBS, Sarah R. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. Journal of Immunology (Baltimore, Md.: 1950). 2011-03-15, roč. 186, čís. 6, s. 3299–3303. PMID: 21317389 PMCID: PMC3198034. Dostupné online [cit. 2018-02-05]. ISSN 1550-6606. DOI 10.4049/jimmunol.1003613. PMID 21317389.
PATSOUKIS, Nikolaos; BARDHAN, Kankana; CHATTERJEE, Pranam. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nature Communications. 2015-03-26, roč. 6. PMID: 25809635 PMCID: PMC4389235. Dostupné online [cit. 2018-02-05]. ISSN 2041-1723. DOI 10.1038/ncomms7692. PMID 25809635.
AMARNATH, Shoba; MANGUS, Courtney W.; WANG, James C. M. The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells. Science Translational Medicine. 2011-11-30, roč. 3, čís. 111, s. 111ra120–111ra120. PMID: 22133721. Dostupné online [cit. 2018-02-14]. ISSN 1946-6234. DOI 10.1126/scitranslmed.3003130. PMID 22133721. (anglicky) Archivováno 1. 6. 2018 na Wayback Machine.
NURIEVA, Roza; THOMAS, Sunil; NGUYEN, Thang. T-cell tolerance or function is determined by combinatorial costimulatory signals. The EMBO Journal. 2006-06-07, roč. 25, čís. 11, s. 2623–2633. PMID: 16724117 PMCID: PMC1478197. Dostupné online [cit. 2018-02-14]. ISSN 0261-4189. DOI 10.1038/sj.emboj.7601146. PMID 16724117.
WANG, Xin; TENG, Feifei; KONG, Li. PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets and Therapy. 2016, roč. 9, s. 5023–5039. PMID: 27574444 PMCID: PMC4990391. Dostupné online [cit. 2019-02-10]. ISSN 1178-6930. DOI 10.2147/OTT.S105862. PMID 27574444.
GANDINI, Sara; MASSI, Daniela; MANDALÀ, Mario. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 2016-4, roč. 100, s. 88–98. PMID: 26895815. Dostupné online [cit. 2019-02-10]. ISSN 1879-0461. DOI 10.1016/j.critrevonc.2016.02.001. PMID 26895815.
SYN, Nicholas L.; TENG, Michele W. L.; MOK, Tony S. K. De-novo and acquired resistance to immune checkpoint targeting. The Lancet. Oncology. 12 2017, roč. 18, čís. 12, s. e731–e741. PMID: 29208439. Dostupné online [cit. 2019-02-10]. ISSN 1474-5488. DOI 10.1016/S1470-2045(17)30607-1. PMID 29208439.
WEBER, Jeffrey. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Seminars in Oncology. 2010-10, roč. 37, čís. 5, s. 430–439. PMID: 21074057. Dostupné online [cit. 2019-02-10]. ISSN 1532-8708. DOI 10.1053/j.seminoncol.2010.09.005. PMID 21074057.
HERBST, Roy S.; SORIA, Jean-Charles; KOWANETZ, Marcin. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014-11-27, roč. 515, čís. 7528, s. 563–567. PMID: 25428504 PMCID: PMC4836193. Dostupné online [cit. 2019-02-10]. ISSN 1476-4687. DOI 10.1038/nature14011. PMID 25428504.
SNYDER, Alexandra; MAKAROV, Vladimir; MERGHOUB, Taha. Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England Journal of Medicine. 2014-12-04, roč. 371, čís. 23, s. 2189–2199. PMID: 25409260 PMCID: PMC4315319. Dostupné online [cit. 2019-02-10]. ISSN 1533-4406. DOI 10.1056/NEJMoa1406498. PMID 25409260.
BUCHBINDER, Elizabeth I.; DESAI, Anupam. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. American Journal of Clinical Oncology. 2016-2, roč. 39, čís. 1, s. 98–106. PMID: 26558876 PMCID: PMC4892769. Dostupné online [cit. 2019-02-10]. ISSN 1537-453X. DOI 10.1097/COC.0000000000000239. PMID 26558876.
TOPALIAN, Suzanne L.; TAUBE, Janis M.; ANDERS, Robert A. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews. Cancer. 05 2016, roč. 16, čís. 5, s. 275–287. PMID: 27079802 PMCID: PMC5381938. Dostupné online [cit. 2019-02-10]. ISSN 1474-1768. DOI 10.1038/nrc.2016.36. PMID 27079802.
CHEN, Daniel S.; MELLMAN, Ira. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013-07-25, roč. 39, čís. 1, s. 1–10. PMID: 23890059. Dostupné online [cit. 2019-02-10]. ISSN 1097-4180. DOI 10.1016/j.immuni.2013.07.012. PMID 23890059.
CURRAN, Michael A.; MONTALVO, Welby; YAGITA, Hideo. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceedings of the National Academy of Sciences of the United States of America. 2010-03-02, roč. 107, čís. 9, s. 4275–4280. PMID: 20160101 PMCID: PMC2840093. Dostupné online [cit. 2019-02-10]. ISSN 1091-6490. DOI 10.1073/pnas.0915174107. PMID 20160101.